Company Description
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.
The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets.
In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
It sells its products through animal health distributors.
ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Country | United States |
IPO Date | May 5, 1987 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 75 |
CEO | Michael F. Brigham |
Contact Details
Address: 56 Evergreen Drive Portland, Maine United States | |
Website | https://immucell.com |
Stock Details
Ticker Symbol | ICCC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000811641 |
CUSIP Number | 452525306 |
ISIN Number | US4525253062 |
Employer ID | 01-0382980 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
Michael F. Brigham | President, Chief Executive Officer, Principal Financial Officer, Treasurer, Secretary & Director |
A. Gustavo Scaffa | Senior Director of Quality |
Bobbi Jo Brockmann | Vice President of Sales & Marketing and Director |
Elizabeth L. Williams | Vice President of Manufacturing Operations |
Elizabeth S. Toothaker | Director of Finance & Administration and Controller |
John W. Zinckgraf | Director of Product Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 09, 2024 | 8-K | Current Report |
Dec 02, 2024 | 8-K | Current Report |
Nov 13, 2024 | 10-Q | Quarterly Report |
Nov 13, 2024 | 8-K | Current Report |
Oct 08, 2024 | 8-K | Current Report |
Sep 24, 2024 | 8-K | Current Report |
Sep 24, 2024 | 4 | Filing |
Sep 24, 2024 | 4 | Filing |
Sep 24, 2024 | 4 | Filing |
Sep 24, 2024 | 4 | Filing |